
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is a strong investment choice as it has shown strong growth and improved cash generation due to a new FDA approved product and expansion plans in the genomics and data segments. With a decrease in interest expenses and a positive cash flow in the future, the company is expected to achieve a CAGR of 25% or higher and has reaffirmed their financial targets. While there may be competition and regulatory concerns, Tempus AI has a diverse portfolio and partnerships with pharmaceutical companies, making it a promising investment option. However, the recent issuance of $400 million in convertible senior notes for debt repayment and general purposes should be monitored.
Bears say
Tempus AI is currently facing challenges with expanding its business due to varying levels of engagement with customers and limited budget allocations for new logo acquisitions, despite its strong presence and partnerships with leading pharmaceutical companies. Additionally, while the company has ambitious goals for growth in its data and diagnostics segments, its recent financial results have seen a widening operating loss. Furthermore, potential volatility in ordering patterns and funding from the US Department of Veteran Affairs for its Million Veteran Program poses a risk to the company's success in the future.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares